Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
"The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people."
Worsening patient outcomes because of care delays call for accelerated AI adoption
About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days.
Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times.
AI has the potential to transform care delivery and significantly improve patient outcomes across APAC.
Workforce challenge and data burdens call for AI relief
Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago.
These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1]
About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented:
Addressing AI concerns from HCPs and patients crucial for widespread adoption
A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes.
Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%).
Trust key to transforming healthcare in APAC
For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area.
For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%).
Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies.
"It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems."
For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips.
About the Future Health Index 2025
The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit www.philips.com/futurehealthindex-2025.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 hours ago
- Korea Herald
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Korea Herald
3 hours ago
- Korea Herald
Interventional Robot's RCT Research Published in JNIS, a Leading Journal in Neurointervention!
SHANGHAI, July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital) in collaboration with Professor Sun Jun (Wenzhou Central Hospital), Professor Chen Wenhuo (Zhangzhou Municipal Hospital of Fujian Province), and Professor Cheng Guangsen (Zhuhai People's Hospital)—have been officially published in the Journal of NeuroInterventional Surgery (JNIS). This milestone marks the first time a China-developed vascular-interventional robot has gained recognition from a premier international neurointerventional journal. Registered as NCT05778214, the trial was designed and executed in strict accordance with regulatory guidelines and Good Clinical Practice (GCP). The prospective, multicenter, non-inferiority RCT enrolled 128 patients undergoing diagnostic cerebral angiography (63 randomized to robot assistance, 65 to conventional manual operation). Results demonstrate that PANVIS-A® is both safe and effective, cutting the primary operator's radiation exposure by 96% while maintaining procedural performance—offering a revolutionary safeguard for physician occupational health. The system received NMPA market authorization on 23 August 2024. 01 Background: A long-awaited breakthrough for neuro-interventional robotics Traditional neurovascular procedures rely entirely on manual manipulation, exposing operators to chronic radiation and limiting precision. Although robotic systems have entered cardiovascular interventions, neuro-intervention imposes far greater demands—intricate anatomy, tortuous vessels, and operative paths exceeding 70 cm from femoral access to intracranial targets. To address this, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. (abrobo) joined forces with leading clinicians to create PANVIS-A®. The platform features the proprietary PANVIS COF® (Catheter On Finger) fingertip-catheter interface, which replicates combined guidewire rotation and catheter advancement in an intuitive manner. A multi-instrument collaborative drive enables sub-millimetric control over long cerebral trajectories, covering the entire workflow from sheath insertion to final angiographic runs and setting a new benchmark for neuro-interventional robotics. 02 Study Design: Rigorous multicenter RCT Prospective, multicenter, randomized, non-inferiority trial. Planned enrollment: 130 patients; actual: 128 (robot 63, manual 65). Allocation ratio 1:1. 03 Key Findings: Three major breakthroughs 1. Safety & efficacy non-inferior to manual approach 2. Radiation exposure to physician reduced by 96 % 3. Efficiency & patient experience Balance operational efficiency with a good patient experience 04 Technical Innovations Master–slave architecture: master console outside radiation field, slave unit on angiography table—precision without exposure. Horizontal control layout: parallel joysticks reproduce in-plane guidewire–catheter geometry, shortening learning curve. PANVIS COF® fingertip interface: fingertip micro-motion replicates combined guidewire rotation and catheter advancement. Dual-grip delivery: biomimetic thumb–index pinch-and-roll for independent or synchronous guidewire/catheter control. Multi-instrument synergy: simultaneous guidewire and catheter manipulation for cooperative motion. Broad compatibility: supports 5F angiographic catheters, 6F guiding catheters, and 0.035ʺ guidewires commonly used in practice. 05 Future Outlook: From diagnostics to full neuro-interventional therapy This study provides high-level evidence that PANVIS-A® can dramatically lower physician radiation exposure without compromising safety or efficiency, paving the way for standardized, intelligent neuro-intervention. To address current limitations (slightly longer setup, modest sample size), abrobo® Innovations has already: Guided by the "in-use, in-development, in-research" roadmap and agile iteration, next-generation PANVIS STAR® has completed its first-in-human study and is entering regulatory submission. Continuous iteration positions PANVIS-A® to become the "standard equipment" in neuro-intervention, propelling China from an "interventional giant" to an "interventional powerhouse" and offering a China-devised solution to neuro-interventionalists worldwide—advancing global health together. About JNIS Launched in 2009, the Journal of NeuroInterventional Surgery (JNIS) is the official journal of the Society of NeuroInterventional Surgery (SNIS) and is published by BMJ. With an impact factor of 4.8 and a JCR Q1 ranking, JNIS sets the gold standard for peer-reviewed research in ischemic stroke, aneurysms, neuro-oncology, and related fields, providing authoritative, evidence-based guidance to clinicians and researchers worldwide.
Korea Herald
8 hours ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
